Skip to main content
Caplight Logo









ImpriMed, Inc.

ImpriMed, Inc.

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://imprimedicine.com

Last Round

Series A

Extension

Sep 18, 2026

Est. Valuation

$47.52M

Total Funding Raised

$37.03M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

ImpriMed, Inc. is a precision medicine company that utilizes artificial intelligence and lab testing of live cancer cells to predict patient response to various cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

veterinary oncologyprecision medicinedrug response predictionvet techAI diagnosticsclinical decision supportchemotherapy selectionveterinary AIdrug sensitivity assaypet cancer treatmentmedical AIusage-based billingbiotechnologyhealthcare analytics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImpriMed, Inc. Comparables

Compare ImpriMed, Inc. with similar companies based on industry and business-model similarity.

ImpriMed, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FidoCure
85%
VetOmics
72%
Anivive Lifesciences
69%

ImpriMed, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 18, 2026
Series ADec 19, 2023
VC RoundApr 13, 2021
SeedApr 12, 2019
Pre SeedJun 1, 2018

Key People

Founding team and executive leadership

Minh B.

Sr. Customer Success EA To The CEO, Biz Ops

Executive Team

Sungwon Lim

CEO, Co-Founder

Founding Team

Mario Castellon

Interim Chief Financial Officer

Executive Team

ImpriMed, Inc. Investors

Notable investors and investment history

ImpriMed, Inc. investors
InvestorRounds
Draper DragonVC Round
StartXSeed
NAVER D2SFSeries A Extension
Plug and Play Tech CenterSeed, Pre Seed
Han River PartnersSeries A
Murex PartnersVC Round, Series A, Seed
Samsung Securities Co., Ltd.Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 18, 2026

    $10M round led by LB Investment.

  • Mar 4, 2026

    Helped over 11,000 dogs and cats with cancer.

Recent news

Latest coverage and updates

  • receives_financingSep 23, 2026

    On Sep 18 '26, ImpriMed, Inc. raises a $10M Series A2 bridge for precision oncology, led by LB Investment with new investors NAVER D2SF, Samsung Securities, and Alois Ventures, alongside returning investors BonAngels and Han River Partners.

  • expands_offices_toSep 18, 2026

    ImpriMed, Inc. expands into Asia as it advances U.S. commercialization through its $10 million Series A2 bridge round, announced in South Korea on Sep 18th '26.

  • is_developingSep 18, 2026

    On Sep 18th '26, ImpriMed, Inc. is developing AI models trained on more than 3.5 million data points that combine real-world data with functional cell analysis to improve predictive accuracy.

  • receives_financingSep 18, 2026

    On Sep 18th '26 in South Korea, ImpriMed, Inc. receives $10M in Series A2 Bridge financing from NAVER D2SF to advance U.S. commercialization and expand into Asia.

ImpriMed, Inc. Filings

Explore SEC and related filing metadata, where available.

ImpriMed, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImpriMed, Inc.'s valuation, stock price, and market status.

Is ImpriMed, Inc. a public or private company?

ImpriMed, Inc. is a private company.

What is the current stock price of ImpriMed, Inc.?

ImpriMed, Inc. is a private company, so its shares have no public market price. Caplight tracks ImpriMed, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is ImpriMed, Inc. worth (valuation)?

ImpriMed, Inc.'s valuation is estimated at $47.5M based on funding round data.

Can I buy ImpriMed, Inc. stock?

ImpriMed, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was ImpriMed, Inc.'s last funding round?

ImpriMed, Inc.'s most recent funding round was Series A Extension on September 18, 2026.

Who are the main investors in ImpriMed, Inc.?

Key investors in ImpriMed, Inc. include Plug and Play Tech Center, SBVA, Draper Associates, LB Investment, HG Initiative.

Will ImpriMed, Inc. IPO soon?

No public IPO plans have been announced for ImpriMed, Inc..

How can I track ImpriMed, Inc. secondary market activity?

Caplight tracks bids, offers, and trades in ImpriMed, Inc.'s shares on secondary markets.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range46
Year Founded2017
Last FundingSep 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?